社论综述：癌症：从靶点发现到靶向治疗——靶点验证的风险业务 - Suppr

Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.

Cruzalegui Francisco

Translational Science, Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK.

Curr Opin Pharmacol. 2014 Aug;17:iv-vi. doi: 10.1016/j.coph.2014.08.004. Epub 2014 Sep 15.

Abstract

摘要

Curr Opin Pharmacol. 2014 Aug;17:iv-vi. doi: 10.1016/j.coph.2014.08.004. Epub 2014 Sep 15.

Drug Discov Ther. 2013 Aug;7(4):129-36.

Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):1-2. doi: 10.1093/abbs/gmv117. Epub 2015 Nov 17.

Methods Mol Biol. 2013;986:3-13. doi: 10.1007/978-1-62703-311-4_1.

Future Oncol. 2012 Aug;8(8):999-1014. doi: 10.2217/fon.12.86.

Curr Opin Pharmacol. 2014 Aug;17:81-6. doi: 10.1016/j.coph.2014.09.004. Epub 2014 Sep 27.

J Pathol. 2014 Jan;232(2):244-54. doi: 10.1002/path.4278.

Cancer Lett. 2012 Dec 31;327(1-2):134-41. doi: 10.1016/j.canlet.2011.12.029. Epub 2012 Jan 24.

Curr Cancer Drug Targets. 2016;16(2):100. doi: 10.2174/156800961602160105154407.

Future Med Chem. 2012 May;4(7):853-67. doi: 10.4155/fmc.12.48.

20分钟写一篇综述，助力文献阅读效率提升50倍。

大模型驱动的PubMed中文搜索引擎

学术文献翻译模型，支持多种主流文档格式。